OptiNose, Inc. (OPTN): Price and Financial Metrics


OptiNose, Inc. (OPTN): $3.64

-0.02 (-0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OPTN POWR Grades


  • OPTN scores best on the Growth dimension, with a Growth rank ahead of 91.86% of US stocks.
  • The strongest trend for OPTN is in Growth, which has been heading up over the past 179 days.
  • OPTN ranks lowest in Momentum; there it ranks in the 12th percentile.

OPTN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OPTN is -3.43 -- better than merely 2.67% of US stocks.
  • OptiNose Inc's stock had its IPO on October 13, 2017, making it an older stock than merely 16.63% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -4.69 for OptiNose Inc; that's greater than it is for only 2.79% of US stocks.
  • If you're looking for stocks that are quantitatively similar to OptiNose Inc, a group of peers worth examining would be BDSX, GLBE, XERS, CSII, and BIOC.
  • Visit OPTN's SEC page to see the company's official filings. To visit the company's web site, go to www.optinose.com.

OPTN Valuation Summary

  • In comparison to the median Healthcare stock, OPTN's price/sales ratio is 77.97% lower, now standing at 2.5.
  • Over the past 47 months, OPTN's price/earnings ratio has gone down 72.4.
  • Over the past 47 months, OPTN's price/sales ratio has gone down 11.7.

Below are key valuation metrics over time for OPTN.

Stock Date P/S P/B P/E EV/EBIT
OPTN 2021-08-31 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-30 2.5 -4.3 -1.7 -2.4
OPTN 2021-08-27 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-26 2.5 -4.1 -1.6 -2.3
OPTN 2021-08-25 2.4 -4.0 -1.6 -2.3
OPTN 2021-08-24 2.4 -4.0 -1.6 -2.3

OPTN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPTN has a Quality Grade of C, ranking ahead of 30.77% of graded US stocks.
  • OPTN's asset turnover comes in at 0.372 -- ranking 127th of 682 Pharmaceutical Products stocks.
  • ALT, FOLD, and RDUS are the stocks whose asset turnover ratios are most correlated with OPTN.

The table below shows OPTN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.372 0.861 -0.687
2021-03-31 0.317 0.854 -0.758
2020-12-31 0.282 0.847 -0.844
2020-09-30 0.258 0.832 -0.995
2020-06-30 0.251 0.840 -1.196
2020-03-31 0.225 0.841 -1.335

OPTN Price Target

For more insight on analysts targets of OPTN, see our OPTN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.4 (Strong Buy)

OPTN Stock Price Chart Interactive Chart >

Price chart for OPTN

OPTN Price/Volume Stats

Current price $3.64 52-week high $3.97
Prev. close $3.66 52-week low $1.46
Day low $3.60 Volume 192,300
Day high $3.97 Avg. volume 306,024
50-day MA $2.45 Dividend yield N/A
200-day MA $2.39 Market Cap 300.96M

OptiNose, Inc. (OPTN) Company Bio


OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.


OPTN Latest News Stream


Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream


Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), BellRing Brands (BRBR) and Optinose (OPTN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), BellRing Brands (BRBR – Research Report) and Optinose (OPTN – Research Report) with bullish sentiments. Regeneron (REGN) BMO Capital analyst Evan Seigerman reiterated a Buy rating on Regeneron today and set a price target of $780.00. The company's shares closed last Friday at $622.96. According to TipRanks.

Catie Powers on TipRanks | February 7, 2022

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Yahoo | January 24, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Yahoo | December 17, 2021

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo 78.43%
3-mo 34.81%
6-mo 92.59%
1-year 21.74%
3-year -45.99%
5-year N/A
YTD 124.69%
2021 -60.87%
2020 -55.10%
2019 48.71%
2018 -67.20%
2017 N/A

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5274 seconds.